Loading clinical trials...
Loading clinical trials...
A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Conditions
Interventions
Nivolumab
Ipilimumab
+1 more
Locations
105
United States
University of Arizona Cancer Center
Tucson, Arizona, United States
Local Institution - 0034
Duarte, California, United States
Los Angeles Cancer Network
Los Angeles, California, United States
Ucla Department Of Medicine
Los Angeles, California, United States
Local Institution - 0098
Redondo Beach, California, United States
Local Institution - 0004
Sacramento, California, United States
Start Date
November 8, 2016
Primary Completion Date
January 23, 2019
Completion Date
April 21, 2022
Last Updated
May 3, 2023
NCT07209189
NCT06477692
NCT04585750
NCT04915183
NCT07457346
NCT06636188
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions